Advertisement
Screener

MANNKIND CORP (MNKD) Unrealized Gain (Loss) on Derivatives

2.9 / 5 stars · 48/83 Roast Me

MANNKIND CORP Unrealized Gain (Loss) on Derivatives

MANNKIND CORP (MNKD) reported Unrealized Gain (Loss) on Derivatives of -$1.24 million for the 283-month period ending 2014-09-30, per its 10-Q filed 2014-11-10.

Discontinued › Cash Flow › Operating Activities

us-gaap:UnrealizedGainLossOnDerivatives · last filed 2015-03-02

  • MANNKIND CORP unrealized gain (loss) on derivatives for the quarter ending 2012-12-31 was -$13.25M.
  • MANNKIND CORP unrealized gain (loss) on derivatives for the quarter ending 2012-09-30 was $0.00.
  • MANNKIND CORP unrealized gain (loss) on derivatives for the quarter ending 2012-06-30 was $10.31M.
  • MANNKIND CORP unrealized gain (loss) on derivatives for the quarter ending 2012-03-31 was $1.71M.
  • MANNKIND CORP unrealized gain (loss) on derivatives for fiscal 2012 was -$1.24M.
Period endUnrealized Gain (Loss) on Derivatives 3 monthUnrealized Gain (Loss) on Derivatives 6 monthUnrealized Gain (Loss) on Derivatives 6 month as first filedUnrealized Gain (Loss) on Derivatives 9 monthUnrealized Gain (Loss) on Derivatives 9 month as first filedUnrealized Gain (Loss) on Derivatives 12 monthUnrealized Gain (Loss) on Derivatives 253 monthUnrealized Gain (Loss) on Derivatives 256 monthUnrealized Gain (Loss) on Derivatives 259 monthUnrealized Gain (Loss) on Derivatives 263 monthUnrealized Gain (Loss) on Derivatives 265 monthUnrealized Gain (Loss) on Derivatives 268 monthUnrealized Gain (Loss) on Derivatives 271 monthUnrealized Gain (Loss) on Derivatives 275 monthUnrealized Gain (Loss) on Derivatives 277 monthUnrealized Gain (Loss) on Derivatives 280 monthUnrealized Gain (Loss) on Derivatives 283 month
2014-09-30-$1.24M
10-Q · filed 2014-11-10
2014-06-30-$1.24M
10-Q · filed 2014-08-11
2014-03-31-$1.24M
10-Q · filed 2014-05-12
2013-12-31-$1.24M
10-K · filed 2014-03-03
2013-09-30-$1.24M
10-Q · filed 2013-11-12
2013-06-30-$1.24M
10-Q · filed 2013-08-09
2013-03-31-$1.24M
10-Q · filed 2013-05-10
2012-12-31-$13.25M
derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02
-$13.25M
derived: sum of 2 quarters · filed 2015-03-02
-$2.94M
derived: sum of 3 quarters · filed 2015-03-02
-$1.24M
10-K · filed 2015-03-02
-$1.24M
10-K · filed 2013-03-18
2012-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12
$10.31M
derived: sum of 2 quarters · filed 2013-11-12
$12.01M
10-Q · filed 2013-11-12
-$12.01M
10-Q · filed 2012-11-09
-$12.01M
10-Q · filed 2012-11-09
2012-06-30$10.31M
derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09
$12.01M
10-Q · filed 2013-08-09
-$12.01M
10-Q · filed 2012-08-09
-$12.01M
10-Q · filed 2012-08-09
2012-03-31$1.71M
10-Q · filed 2013-05-10
$1.71M
10-Q · filed 2012-05-10

Similar stocks

Stock NameCountryMarket CapPE Ratio
Alto Neuroscience, Inc. (ANRO)United States$1.065B-11.02
Savara Inc (SVRA)United States$1.044B-9.10
MoonLake Immunotherapeutics (MLTX)Switzerland$1.031B-5.43
Pacira BioSciences, Inc. (PCRX)United States$1.020B69.03
Janux Therapeutics, Inc. (JANX)United States$1.019B-9.15
Amphastar Pharmaceuticals, Inc. (AMPH)United States$1.116B10.93
Corvus Pharmaceuticals, Inc. (CRVS)United States$0.994B-23.25
Seaport Therapeutics, Inc. (SPTX)United States$1.131B
Kura Oncology, Inc. (KURA)United States$0.967B-3.29
Arbutus Biopharma Corp (ABUS)$0.965B6.19